תבנית:תרופה/אלבונורם 20% - Albunorm 20%

× ×ª×× × ×ª×¨××¤×

×××¨×©×

××× ×× ×× × ××¡×¤××	××××× ××¨× 5% - Albunorm 5%
×§×××¦× ×¤×¨××§××××××ª (ATC4)	B05AA Blood substitutes and plasma protein fractions
××¨××× ×¤×¢×× (ATC5)	Â Albumin human 200G / 1000 ML âB05AA01 Albumin human 200G / 1000 ML âB05AA01 Plasma protein fraction 96% âB05AA01 Blood substitutes and plasma protein fractions B05AA âB05AA01 Wolfgang-marguerre-alle 1, D-31832 SPRINGE, GERMANY release , primary packaging , bulk , intermediate âB05AA01 Lars forssells gata 23 SE-112 75 STOCKHOLM, SWEDEN release , primary packaging , bulk , intermediate âB05AA01 Otto - reuter - strasse 3, 06847 DESSAU-ROSSLAU, GERMANY labelling , secondary packaging âB05AA01 Oberlaaer strasse 235, A-1100 VIENNA, AUSTRIA release , labelling , secondary packaging , primary packaging , bulk , intermediate âB05AA01 72 rue du marechal foch 67380 LINGOLSHEIM, FRANCE release , primary packaging , bulk , intermediate âB05AA01 Albumin human 200G / 1000 ML âB05AA01 Plasma protein fraction 96% âB05AA01
×¦××¨×ª ××ª×	×ª××-××¨××× - I.V
×¦××¨×ª ××× ××	×ª×××¡× ×××× ×¤××××, SOLUTION FOR INFUSION ××× ××¢×ª ××× ×× ××ª×¨ ×× ××¨×¢×× ××© ××××× ××ª ××ª×¨××¤× ×××ª×× ×××× ×× ××××××¥ ××¤× ×©×××¤××¢ ××¢××× ××¦×¨××
××ª××××	Restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated, and use of a colloid is appropriate.The choice of albumin rather than artificial colloid will depend on the clinical situation of the individual patient, based on the official recommendations
××ª×××ª ××× ××	Posology and method of administration
××ª×××××ª × ××	Contraindications
×ª××¤×¢××ª ×××××	Undesirable effects
×ª×××××ª ××× ×ª×¨××¤×ª×××ª	Interaction with other medicinal products and other forms of interaction
×©××××© ××××¨××× ××× ×§×	Pregnancy and Lactation
×¤×¨××§×××× ×××§×	Pharmacodynamic Properties
×¤×¨××§××§×× ×××§×	Pharmacokinetic Properties
×¢××× ××¨××¤× ×××××¨××ª ××¢×××	×¢××× ××¨××¤×

×¢×¨××× ×××××§××¨×¤×××	×¢×¨××× ×§×©××¨×× ×××××§××¨×¤×××
××××× ××¨× 20% Â® ×××××¨ ××©×¨× ×××¨××××ª

×××¤××© ××××¨××	-
××××¢ ××¨×©×ª	-
×©× ××¦×¨×	OCTAPHARMA AG, SWITZERLAND
×©× ××¢× ××¨××©××	DOVER MEDICAL & SCIENTIFIC EQUIPMENT LTD, ISRAEL
×¨××©×××	×ª××¨×× ×××©×: 06/2012. ×¨××©××× ××ª××¨××: 06/2018
×ª××¨×× ×¢×××× ×××¨××	14/05/19

××£ ×× × ××¦×¨ ×¢× ××× ××× ××××××¨ ×ª×× ××ª ×¢× ×¤×¨×× ××ª×¨××¤×.

××£ ××ª×¨××¤×: ××××× ××¨× 20% - Albunorm 20%

{{×ª×¨××¤×/××××× ××¨× 20% - Albunorm 20%}}

×:

{{×ª×¨××¤×/××××× ××¨× 20% - Albunorm 20%
| ×©× ××¤×¨×××¨=×¢×¨× ×××© (×××¨×¡ ××ª ××¢×¨× ×©×××× ×××××¨)
}}

השינוי האחרון נעשה בֹ־9 ביוני 2021 ב־11:39

תבנית:תרופה/אלבונורם 20% - Albunorm 20%

ויקיתרופות